Търсене на изпитвания

Активни:

Намерени 3,079 изпитвания Стр. 108 от 154

Активно (без набиране) Фаза 3

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Multiple Myeloma

The purpose of this study is to compare the efficacy, safety, and tolerability of ide-cel with lenalidomide (LEN) maintenance to that of LEN maintenance alone in adult participants with Newly Diagnosed Multiple Myeloma (NDMM) who have achieved a suboptimal response post autologous stem cell transplantation (ASCT).

Начало: 16.10.2023 Край: 20.11.2029 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +13 Celgene NCT06045806

Активно (без набиране) Фаза 1

Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers

Advanced Cancer Advanced Malignancies Bladder Cancer Cervical Cancer +8

The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.

Начало: 13.10.2023 Край: 01.03.2026 Възраст: от 18 г. Лечение

Australia, Taiwan, United States Arcus Biosciences, Inc. NCT05891171

Активно (без набиране) Фаза 3

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Начало: 12.10.2023 Край: 06.04.2027 Възраст: от 12 г. Лечение

Argentina, Australia, Canada +13 Janssen Research & Development, LLC NCT06095115

Активно (без набиране) Фаза 3

A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

Multiple Myeloma

The purpose of this study is to compare the efficacy of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Ciltacabtagene Autoleucel versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple myeloma patients.

Начало: 10.10.2023 Край: 01.08.2040 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +12 Stichting European Myeloma Network NCT05257083

Активно (без набиране) Фаза 1

Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors

Solid Tumors

The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: * Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors * Identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended dose for expansion (RDE) of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors

Начало: 09.10.2023 Край: 01.12.2026 Възраст: от 18 г. Лечение

Australia, Canada, United States Gilead Sciences NCT06082960

Активно (без набиране) Фаза 2

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous Squamous Cell Carcinoma.

Начало: 09.10.2023 Край: 28.09.2026 Възраст: от 18 г. Лечение

Australia, Brazil, Canada +12 Incyte Corporation NCT05888844

Активно (без набиране) Фаза 3

A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma

Follicular Lymphoma (FL)

This trial will compare tisagenlecleucel to standard of care in adult participants with relapsed or refractory (r/r) follicular lymphoma.

Начало: 02.10.2023 Край: 20.02.2031 Възраст: 18–100 г. Лечение

Australia, Canada, Czechia +7 Novartis Pharmaceuticals NCT05888493

Активно (без набиране) Фаза 1

A Study to Evaluate Safety, Pharmacokinetics, & Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-care Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors; Urothelial Carcinoma Substudy in Association With RO7496353 Study GO44010

Non-small Cell Lung Cancer Gastric Cancer Pancreatic Ductal Adenocarcinoma

The purpose of this study is to evaluate the safety and tolerability of RO7496353 in combination with a checkpoint inhibitor (CPI) with or without standard-of-care (SOC) chemotherapy in participants with locally advanced or metastatic solid tumors such as non-small cell lung cancer (NSCLC), gastric cancer (GC) and pancreatic ductal adenocarcinoma (PDAC). The substudy will evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumor activity of RO7496353 in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC). The parent and substudy will be conducted in 2 stages: an initial safety run-in stage and an expansion stage.

Начало: 02.10.2023 Край: 30.06.2026 Възраст: от 18 г. Лечение

Australia, Brazil, Italy +6 Genentech, Inc. NCT05867121

Активно (без набиране)

Acuity 200™ (Fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear

Myopia

The objective of this clinical investigation is to collect scientifically valid safety and effectiveness data on the Acuity 200™ (fluoroxyfocon A) Orthokeratology Contact Lens for Overnight Wear. The clinical performance data reported from this study is intended to be submitted to the U.S. Food and Drug Administration Center for Devices and Radiological Health (CDRH) in support of a new Premarket Application (PMA).

Начало: 01.10.2023 Край: 01.09.2025 Възраст: от 7 г. Лечение

Australia, New Zealand, United States Acuity Polymers, Inc. NCT06009458

Активно (без набиране) Фаза 1

Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

Chronic Hepatitis B

This Phase 1b clinical study is a multi-center, open-label, dose escalation, prime only, and prime plus boost therapeutic vaccination study of 2 distinct chimpanzee adenoviral vectors (AdC6 and AdC7), containing parts of hepatitis B virus (HBV) core and polymerase antigens fused within glycoprotein D in a cohort of chronic hepatitis B (CHB)-infected adult participants who are currently receiving entecavir, tenofovir (tenofovir alafenamide fumarate or tenofovir disoproxil fumarate), or lamivudine, with documented HBV viral load suppression for at least 12 months. Approximately 24 participants will be enrolled in Group 1 and randomized to Cohort 1a or Cohort 1b. Those assigned to Cohort 1a will receive a low dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 1b will receive a low dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination. Group 2 will then enroll approximately 24 participants randomized to Cohort 2a or Cohort 2b. Those assigned to Cohort 2a will receive a high dose prime therapeutic vaccination of vector AdC7 on Day 1, followed by a booster vaccination on Day 91 using vector AdC6. Those assigned to Cohort 2b will receive a high dose prime therapeutic vaccination of vector AdC6 on Day 1, and will not receive a booster vaccination. Group 3 will enroll approximately 8 participants randomized into Cohort 3a or Cohort 3b. Cohort 3a will receive the high dose prime VRON-0200 vaccination of vector AdC7 on Day 1, followed by doses of VIR-2218 plus VIR-3434 on Days 28, 56, 84, 112, 140 and 168, and then a booster using a high dose VRON-0200 vaccination of vector AdC6 on Day 196. Cohort 3b will receive the same high dose prime VRON-0200 vaccination of vector AdC7 followed by 6 doses of VIR-2218 plus VIR-3434 at the same timepoints as Cohort 3a, but will not receive the booster dose on Day 196. VRON-0200 vaccine doses will be administered by intramuscular (IM) injection. VIR-2218 and VIR-3434 will be administered subcutaneously. All study participants will be followed for a total of 1 year post-prime vaccination.

Начало: 26.09.2023 Край: 31.03.2026 Възраст: 18–55 г. Лечение

Hong Kong, New Zealand Virion Therapeutics NCT06070051

Активно (без набиране) Фаза 1/2

Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT)

Rett Syndrome

This 18-week open-label study examines the effectiveness of Full-Spectrum Medicinal Cannabis Plant Extract containing 0.08% THC (NTI164) in treating Rett syndrome (RTT) in children and young people. The study aims to determine the impact of NTI164 on RTT symptoms over a 16-week treatment period. Participants will start with a daily dose of 5 mg/kg of NTI164, which will be gradually increased over four weeks until they reach either the maximum tolerated dose or 20 mg/kg per day. They will then maintain this dose for eight weeks. Following this treatment phase, the dosage will be reduced by 5 mg/kg each week for four weeks until treatment concludes. The effectiveness of the treatment will be assessed using tailored questionnaires that measure changes in the patients\' conditions. Additionally, full blood examinations will be conducted at multiple points throughout the study to monitor the effects of the treatment.

Начало: 20.09.2023 Край: 01.12.2025 Възраст: 5–20 г. Лечение

Australia Fenix Innovation Group NCT06621043

Активно (без набиране) Фаза 3

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

Large B-Cell Lymphoma

The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs Pola-R-CHP in participants with previously untreated CD20-positive large B-cell lymphoma (LBCL).

Начало: 18.09.2023 Край: 30.10.2030 Възраст: 18–80 г. Лечение

Argentina, Australia, Belgium +17 Hoffmann-La Roche NCT06047080

Активно (без набиране) Фаза 3

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Начало: 14.09.2023 Край: 04.06.2027 Възраст: от 40 г. Лечение

Argentina, Australia, Belgium +27 Bristol-Myers Squibb NCT06003426

Активно (без набиране) Фаза 3

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

Hepatocellular Carcinoma

The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic HCC. Per amendment version 5, following a memo issued by the Sponsor, participants receiving treatment in the atezolizumab plus bevacizumab plus tiragolumab arm are recommended to discontinue tiragolumab treatment unless the investigator decides the benefit outweighs the risk. Participants receiving treatment in atezolizumab plus bevacizumab plus placebo arm must discontinue placebo treatment. Participants may continue receiving active treatment(s) per protocol until loss of clinical benefit or unacceptable toxicity, whichever occurs first.

Начало: 14.09.2023 Край: 01.09.2026 Възраст: от 18 г. Лечение

Belgium, Brazil, Canada +24 Hoffmann-La Roche NCT05904886

Активно (без набиране)

A Study Evaluating the Application of Hearing Aid Technologies to Signal Processing for Adult Cochlear Implant Recipients

Hearing Loss

A feasibility, prospective, multi-centre, repeated measures investigation evaluating the application of hearing aid technologies to signal processing for adult cochlear implant recipients

Начало: 11.09.2023 Край: 30.06.2026 Възраст: от 18 г. Друго

Australia Cochlear NCT05866770

Активно (без набиране) Фаза 3

A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome

Sjögren's Syndrome

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Начало: 11.09.2023 Край: 16.11.2028 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +27 Bristol-Myers Squibb NCT05946941

Активно (без набиране) Фаза 2

Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine

Bronchiectasis

This study is open to adults aged 18 years and older with bronchiectasis. People can join the study if they were previously enrolled in another study with BI 1291583 (1397-0012: Airleafᵀᴹ or 1397-0013 Clairaflyᵀᴹ). The purpose of this study is to find out whether a medicine called BI 1291583 helps people with bronchiectasis, an inflammatory lung condition. The investigators also want to know how well people with this condition can tolerate BI 1291583 in the long term. Participants take a low, medium, or high dose of BI 1291583 as a tablet once a day for up to 1 year. Participants who were taking placebo in the AirleafTM or ClairaflyTM study are put into the BI 1291583 dosage groups randomly, which means by chance. Placebo tablets look like BI1291583 but do not contain any medicine. Participants who were taking BI 1291583 in the AirleafTM or ClairaflyTM study continue to take the same dose. Participants visit the study site 10 times and get 4 phone calls from the site staff. During the visits, the doctors collect information on any health problems of the participants. The doctors also check whether BI 1291583 helps reduce the symptoms of bronchiectasis.

Начало: 08.09.2023 Край: 31.03.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Bulgaria +17 Boehringer Ingelheim NCT05846230

Активно (без набиране) Фаза 2

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma Refractory

This is an open label, multi-centre, phase II study in which RR MCL patients will be genetically risk-stratified into Standard risk (no 9p21.1-24.3 loss, no SMARCA2 or SMARCA4 mut/del) and High risk (9p21.1-24.3 loss, SMARCA2 and/or SMARCA4 mut/del). Patients without the high-risk mutations will be treated with ibrutinib, rituximab and venetoclax. Patients with the high-risk mutations will be treated with ibrutinib, rituximab, venetoclax and navitoclax.

Начало: 07.09.2023 Край: 01.06.2029 Възраст: от 18 г. Лечение

Australia Peter MacCallum Cancer Centre, Australia NCT05864742

Активно (без набиране) Фаза 1

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Non-Small Cell Lung Cancer Pancreatic Cancer Locally Advanced Solid Tumor Metastatic Solid Tumor

This is a phase 1b multi-center, open-label study of HMBD-001 with or without chemotherapy in participants with advanced solid tumors harboring NRG1 gene fusions or selected HER3 mutations.

Начало: 06.09.2023 Край: 01.03.2031 Възраст: от 18 г. Лечение

Australia Hummingbird Bioscience NCT05919537

Активно (без набиране)

Enlighten Study: The EV-ICD Post Approval Registry

Ventricular Arrhythmia Tachycardia

Medtronic is sponsoring Enlighten: The EV-ICD Post Approval Registry, to further confirm safety and effectiveness of EV-ICD in routine clinical practice, following commercial release of EV-ICD devices.

Начало: 01.09.2023 Край: 31.10.2037

Austria, Belgium, Canada +18 Medtronic NCT06048731

1 … 106 107 108 109 110 … 154